查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087907

Activin-A 市場：按產品類型、配方、給藥途徑、分銷管道、最終用戶和應用分類的全球市場預測，2026-2032 年

Activin-A Market by Product Type, Formulation, Route Of Administration, Distribution Channel, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，Activin-A 市場將成長至 5.2132 億美元，複合年成長率為 6.55%。

主要市場統計數據
基準年 2025 3.3432億美元
預計年份：2026年 3.567億美元
預測年份 2032 5.2132億美元
複合年成長率 (%) 6.55%

由INHBA基因編碼，作為轉化生長因子-BETA (TGF-BETA) 超家族的二聚體發揮作用的激活素A，是生命科學、生物製藥研究、診斷和轉化醫學中的關鍵靶點。它透過激活素II受體和下游SMAD2/3訊號通路進行訊號傳導，與生殖生物學、發炎、纖維化、肌肉代謝、傷口修復、幹細胞分化以及多種癌症相關過程密切相關。

隨著治療藥物研發者、診斷技術創新者和研究工具供應商將關注點從單一疾病應用擴展到基於訊號路徑的平台，激活素A領域正日益受到關注。這一發展勢頭得益於同行評審的證據，這些證據表明激活素A是一種可測量的疾病相關生物標記；重組蛋白、抗體和免疫檢測的日益普及；以及人們對TGF-BETA超家族調控作為激活素通路療法監管進展的重新關注。

激活素A領域的變革性變化

激活素A的研究領域正從探索性生物學研究轉向轉化研究和商業性化計畫。關於INHBA表現、纖維化訊號傳導、腫瘤微環境調控、骨骼肌萎縮、生殖內分泌和發炎性疾病進展等方面的科學發現正日益被整合到生物標記組合、藥物研發流程和病患分層模型中。

人工智慧的累積影響

人工智慧正在加速激活素A的研究，其途徑包括改進標靶檢驗、分子設計、生物標記發現和臨床試驗規劃。機器學習模型可以整合轉錄組學、蛋白質組學、影像學、電子健康記錄和臨床終點數據，從而識別激活素A訊號通路最有可能有效發揮作用的疾病情況。

關鍵區域洞察

亞太地區正崛起為激活素A研究的重要中心，這主要得益於中國、日本、韓國、印度、澳洲和東協市場強大的生物製造能力、不斷完善的臨床試驗基礎設施以及政府主導的生物技術計畫。腫瘤學、再生醫學、不孕症研究和生技藥品生產能力為該地區的激活素A研究活動提供了支持，從而帶動了檢驗的抗體、重組蛋白、ELISA試劑盒和轉化生物標記檢測的需求成長。

關鍵群體特定見解

在醫療保健投資不斷成長、該地區臨床試驗活動日益活躍、醫療旅遊活性化以及對具成本效益生物標記工具的需求推動下，東協市場正成為激活素A相關診斷和臨床研究的理想市場。海灣合作理事會（GCC）成員國正日益重視精準醫療、專科醫療、基因組學計畫以及國家級生命科學戰略，這為與先進的生物製藥、伴隨診斷、轉化研究和標準檢測實驗室開展合作創造了機會。

主要國家的概況

美國憑藉其生物製藥研發管線、美國國立衛生研究院 (NIH) 支持的訊號通路研究、美國食品藥物管理局 (FDA) 監管的生技藥品開發、學術轉化研究中心、專業診斷技術以及雄厚的創業融資。加拿大則透過免疫學、再生食品藥物管理局、幹細胞科學和臨床研究網路做出貢獻，而墨西哥則提供了更多參與臨床試驗的機會，並滿足了對價格合理的診斷產品的需求。巴西是拉丁美洲的主要貢獻者，其學術腫瘤學、生殖健康、發炎性疾病研究以及公共部門生物醫學機構都為此提供了支持。

為行業領導者提供的實用建議

產業領導者應優先選擇那些具有強力人體組織數據、可重複生物標記和明確臨床終點支持的激活素A生物學特性的適應症。每個項目都應區分激活素A特異性效應和更廣泛的激活素受體訊號傳導，並在不同的基質、目標人群、疾病階段和治療環境中檢驗。

調查方法

本調查方法結合了二手資料研究、監管資訊、科學文獻綜述、專利映射、臨床試驗追蹤和專家解讀。所考慮的資訊來源包括同行評審期刊、公共臨床試驗註冊庫、監管公告、資助資料庫、專利庫、生物醫學本體以及經過驗證的蛋白質、基因表現和檢驗路徑資料庫。

結論

激活素A已從專門的研究性蛋白質轉變為生物標記科學和治療創新領域的策略基石。由於其在發炎、纖維化、腫瘤學、生殖醫學、血管生物學、組織重塑、幹細胞分化和肌肉代謝中發揮的作用，激活素A與多種棘手的疾病領域密切相關。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 Activin-A 市場：依產品類型分類

  • 類似產品
  • 生物相似藥Activin-A
  • 重組激活素A

第8章 Activin-A 市場：依劑型分類

  • 液體
  • 凍乾粉

第9章：Activin-A市場：依給藥途徑分類

  • 注射藥物
  • 外用

第10章：Activin-A 市場：依通路分類

  • 離線
  • 線上

第11章 Activin-A 市場：依最終用戶分類

  • 學術研究機構
  • 受託研究機構
  • 醫院和診所
  • 製藥和生物技術公司

第12章 Activin-A 市場：依應用領域分類

  • 骨再生
  • 藥物發現
    • 高通量篩檢
    • 目標檢驗
  • 組織工程
    • 心臟組織工程
    • 神經組織工程
    • 皮膚組織工程
  • 創傷治療
    • 燒燙傷恢復
    • 糖尿病足潰瘍
    • 壓瘡

第13章 Activin-A 市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 Activin-A 市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 Activin-A 市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abcam Limited
  • ACROBiosystems Group
  • Agilent Technologies Inc
  • Aviva Systems Biology Corporation
  • Bio-Rad Laboratories Inc
  • Bio-Techne Corporation
  • BioLegend Inc
  • BPS Bioscience Inc
  • Cell Sciences Inc
  • Cell Signaling Technology Inc
  • Creative BioMart Inc
  • GenScript Biotech Corporation
  • Kingfisher Biotech Inc
  • Lonza Group AG
  • Merck KGaA
  • Miltenyi Biotec BV & Co KG
  • OriGene Technologies Inc
  • ProSpec-Tany TechnoGene Ltd
  • Proteintech Group Inc
  • Qkine Ltd
  • RayBiotech Life Inc
  • Shenandoah Biotechnology Inc
  • Sino Biological Inc
  • Takara Bio Inc
  • Thermo Fisher Scientific Inc
Product Code: MRR-035DA3C6369C

The Activin-A Market is projected to grow by USD 521.32 million at a CAGR of 6.55% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 334.32 million
Estimated Year [2026] USD 356.70 million
Forecast Year [2032] USD 521.32 million
CAGR (%) 6.55%

Activin-A, encoded by INHBA and functioning as a dimeric member of the transforming growth factor-beta superfamily, is a high-value target across life sciences, biopharmaceutical research, diagnostics, and translational medicine. Its signaling through activin type II receptors and downstream SMAD2/3 pathways links it to reproductive biology, inflammation, fibrosis, muscle metabolism, wound repair, stem-cell differentiation, and multiple cancer-associated processes.

The Activin-A landscape is gaining visibility as therapeutic developers, diagnostic innovators, and research-tool suppliers look beyond single-disease applications toward pathway-based platforms. Momentum is supported by peer-reviewed evidence identifying Activin-A as a measurable disease-associated biomarker, expanding use of recombinant proteins, antibodies, and immunoassays, and renewed scientific interest in TGF-beta superfamily modulation following regulatory progress in activin pathway therapeutics.

Transformative Shifts in the Activin-A Landscape

The Activin-A landscape is shifting from exploratory biology toward translational and commercially actionable programs. Academic discoveries around INHBA expression, fibrosis signaling, tumor microenvironment regulation, skeletal muscle wasting, reproductive endocrinology, and inflammatory disease progression are increasingly being integrated into biomarker panels, drug-discovery workflows, and patient-stratification models.

A second transformation is the movement from broad pathway suppression to more selective modulation of activin signaling. Ligand traps, receptor-directed biologics, neutralizing antibodies, and engineered protein approaches are being assessed with greater attention to target selectivity, safety, pharmacodynamics, and disease-specific biology. This shift is especially important because activin ligands overlap functionally with other TGF-beta family members, requiring careful validation of mechanism, assay specificity, and clinical relevance.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating Activin-A research by improving target validation, molecular design, biomarker discovery, and trial planning. Machine learning models can integrate transcriptomics, proteomics, imaging, electronic health records, and clinical endpoints to identify disease settings where Activin-A signaling is most likely to be actionable.

AI-enabled protein modeling, structure-guided engineering, and predictive toxicology are also influencing biologic design around activin receptors and ligand-binding domains. In clinical development, AI can improve cohort selection by identifying INHBA-driven molecular phenotypes, while real-world evidence analytics can help monitor response patterns, adverse events, and combination opportunities across inflammation, oncology, fibrosis, pulmonary vascular disease, reproductive health, and metabolic disorders.

Key Regional Insights

Asia-Pacific is emerging as a major center for Activin-A research due to strong biomanufacturing capacity, expanding clinical trial infrastructure, and government-backed biotechnology initiatives in China, Japan, South Korea, India, Australia, and ASEAN markets. Regional activity is reinforced by oncology, regenerative medicine, fertility research, and biologics manufacturing capabilities, with rising demand for validated antibodies, recombinant proteins, ELISA kits, and translational biomarker assays.

North America remains the most mature commercialization hub, supported by NIH-funded basic research, FDA regulatory pathways for biologics, venture investment, academic medical centers, and advanced diagnostic laboratories. Latin America is building relevance through Brazil and Mexico, where oncology, reproductive medicine, and inflammatory disease research create demand for validated biomarkers and clinical assays. Europe benefits from EMA oversight, Horizon Europe-funded biomedical research, and strong academic networks in Germany, France, Italy, Spain, and the United Kingdom. The Middle East is advancing through GCC precision medicine investment, specialty care infrastructure, and national life-science strategies, while Africa is gradually expanding capacity in genomics, infectious disease research, maternal health studies, and population-based clinical research.

Key Group Insights

ASEAN markets are becoming attractive for Activin-A-related diagnostics and clinical research because of rising healthcare investment, regional trial activity, medical tourism, and demand for cost-effective biomarker tools. The GCC is positioning itself around precision medicine, specialty care, genomics programs, and national life-science strategies, creating opportunities for advanced biologics, companion diagnostics, translational research, and reference-laboratory partnerships.

The European Union offers one of the strongest regulatory and research environments for activin pathway science, particularly through coordinated clinical standards, cross-border funding, centralized medicines regulation, and multicenter research networks. BRICS countries provide scale, manufacturing capacity, and diverse patient populations for biomarker validation and biologics development, while G7 economies lead in intellectual property creation, advanced biologics, regulatory science, high-quality clinical evidence, and premium diagnostics. NATO-linked countries add relevance through biosecurity, health resilience, supply-chain security, and dual-use governance frameworks affecting advanced biotechnology, recombinant proteins, and biomarker platforms.

Key Country Insights

The United States leads in Activin-A innovation through biopharma pipelines, NIH-supported pathway research, FDA-regulated biologics development, academic translational centers, specialty diagnostics, and strong venture financing. Canada contributes through immunology, regenerative medicine, stem-cell science, and clinical research networks, while Mexico offers expanding clinical trial access and demand for affordable diagnostics. Brazil is the leading Latin American contributor, supported by academic oncology, reproductive health, inflammatory disease research, and public-sector biomedical institutions.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain strong roles in translational biology, clinical trials, reproductive medicine, oncology research, and specialty diagnostics, while Russia retains scientific expertise in molecular biology and immunology but faces market-access and international collaboration constraints. China is scaling biologics manufacturing, oncology research, and domestic innovation in recombinant proteins and antibodies; India is expanding biopharma services, biosimilar capabilities, and cost-efficient trials; Japan emphasizes regenerative medicine, pulmonary vascular disease research, and high-quality translational science; Australia supports early-phase clinical development and academic biomarker research; and South Korea combines advanced biologics manufacturing with strong precision-medicine adoption and government-backed biotechnology programs.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize indication selection where Activin-A biology is strongly supported by human tissue data, reproducible biomarkers, and clear clinical endpoints. Programs should distinguish Activin-A-specific effects from broader activin receptor signaling and should validate assays across matrices, populations, disease stages, and treatment settings.

Commercially, organizations should build partnerships across academic centers, contract research organizations, specialty diagnostic labs, biologics manufacturers, and regulatory specialists. Differentiation will depend on mechanism clarity, companion diagnostic readiness, intellectual property strength, scalable manufacturing, early regulatory engagement, and evidence generation that links INHBA expression or circulating Activin-A levels to clinically meaningful outcomes.

Research Methodology

The research methodology combines secondary research, regulatory intelligence, scientific literature review, patent mapping, clinical trial tracking, and expert-led interpretation. Sources considered include peer-reviewed journals, public clinical trial registries, regulatory agency communications, funding databases, patent repositories, biomedical ontologies, and validated protein, gene-expression, and pathway databases.

Findings are triangulated across disease biology, product modality, regional activity, competitive positioning, and commercialization readiness. Emphasis is placed on reproducible evidence, mechanistic plausibility, regulatory relevance, assay validation, and observable signals from therapeutics, diagnostics, recombinant proteins, antibodies, assay kits, and contract research services, while avoiding unsupported sizing or forecasting assumptions.

Conclusion

Activin-A has moved from a specialized research protein to a strategic node in biomarker science and therapeutic innovation. Its role in inflammation, fibrosis, oncology, reproductive medicine, vascular biology, tissue remodeling, stem-cell differentiation, and muscle metabolism makes it relevant to multiple high-burden disease areas.

Future adoption will depend on selective pathway modulation, robust clinical validation, scalable manufacturing, validated assays, and AI-enhanced evidence generation. Organizations that combine rigorous biology with disciplined commercialization strategies, regulatory readiness, and clinically meaningful biomarker development are best positioned to capture value in the evolving Activin-A landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Activin-A Market, by Product Type

  • 7.1. Analogues
  • 7.2. Biosimilar Activin-A
  • 7.3. Recombinant Activin-A

8. Activin-A Market, by Formulation

  • 8.1. Liquid Solution
  • 8.2. Lyophilized Powder

9. Activin-A Market, by Route Of Administration

  • 9.1. Injectable
  • 9.2. Topical

10. Activin-A Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Activin-A Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals And Clinics
  • 11.4. Pharmaceutical Biotech Companies

12. Activin-A Market, by Application

  • 12.1. Bone Regeneration
  • 12.2. Drug Discovery
    • 12.2.1. High Throughput Screening
    • 12.2.2. Target Validation
  • 12.3. Tissue Engineering
    • 12.3.1. Cardiac Tissue Engineering
    • 12.3.2. Neural Tissue Engineering
    • 12.3.3. Skin Tissue Engineering
  • 12.4. Wound Healing
    • 12.4.1. Burn Restoration
    • 12.4.2. Diabetic Foot Ulcer
    • 12.4.3. Pressure Ulcer

13. Activin-A Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Activin-A Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Activin-A Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abcam Limited
  • 17.2. ACROBiosystems Group
  • 17.3. Agilent Technologies Inc
  • 17.4. Aviva Systems Biology Corporation
  • 17.5. Bio-Rad Laboratories Inc
  • 17.6. Bio-Techne Corporation
  • 17.7. BioLegend Inc
  • 17.8. BPS Bioscience Inc
  • 17.9. Cell Sciences Inc
  • 17.10. Cell Signaling Technology Inc
  • 17.11. Creative BioMart Inc
  • 17.12. GenScript Biotech Corporation
  • 17.13. Kingfisher Biotech Inc
  • 17.14. Lonza Group AG
  • 17.15. Merck KGaA
  • 17.16. Miltenyi Biotec B.V. & Co KG
  • 17.17. OriGene Technologies Inc
  • 17.18. ProSpec-Tany TechnoGene Ltd
  • 17.19. Proteintech Group Inc
  • 17.20. Qkine Ltd
  • 17.21. RayBiotech Life Inc
  • 17.22. Shenandoah Biotechnology Inc
  • 17.23. Sino Biological Inc
  • 17.24. Takara Bio Inc
  • 17.25. Thermo Fisher Scientific Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACTIVIN-A MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ACTIVIN-A MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ACTIVIN-A MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ACTIVIN-A MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACTIVIN-A MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ACTIVIN-A MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACTIVIN-A MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ACTIVIN-A MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ACTIVIN-A MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ACTIVIN-A MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ACTIVIN-A MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ACTIVIN-A MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ACTIVIN-A MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ACTIVIN-A MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ACTIVIN-A MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ACTIVIN-A MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ACTIVIN-A MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ACTIVIN-A MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANALOGUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANALOGUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOSIMILAR ACTIVIN-A MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOSIMILAR ACTIVIN-A MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOSIMILAR ACTIVIN-A MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RECOMBINANT ACTIVIN-A MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RECOMBINANT ACTIVIN-A MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RECOMBINANT ACTIVIN-A MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIQUID SOLUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LIQUID SOLUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIQUID SOLUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACEUTICAL BIOTECH COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACEUTICAL BIOTECH COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACEUTICAL BIOTECH COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BONE REGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BONE REGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BONE REGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HIGH THROUGHPUT SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TARGET VALIDATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TARGET VALIDATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TARGET VALIDATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TISSUE ENGINEERING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TISSUE ENGINEERING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CARDIAC TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEURAL TISSUE ENGINEERING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEURAL TISSUE ENGINEERING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEURAL TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SKIN TISSUE ENGINEERING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SKIN TISSUE ENGINEERING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SKIN TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL WOUND HEALING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL WOUND HEALING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL WOUND HEALING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BURN RESTORATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BURN RESTORATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BURN RESTORATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIABETIC FOOT ULCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIABETIC FOOT ULCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIABETIC FOOT ULCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PRESSURE ULCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PRESSURE ULCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PRESSURE ULCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACTIVIN-A MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ACTIVIN-A MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 155. GCC ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. GCC ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 158. GCC ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 164. GCC ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 185. G7 ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. G7 ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. G7 ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. G7 ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. G7 ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 194. G7 ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 195. NATO ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. NATO ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 198. NATO ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. NATO ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. NATO ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. NATO ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 203. NATO ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 204. NATO ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL ACTIVIN-A MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. CANADA ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 224. CANADA ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 225. CANADA ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 226. MEXICO ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. MEXICO ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. MEXICO ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. BRAZIL ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. BRAZIL ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 244. BRAZIL ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 256. GERMANY ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. GERMANY ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 266. FRANCE ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. FRANCE ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. FRANCE ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. FRANCE ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 274. FRANCE ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. RUSSIA ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 286. ITALY ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. ITALY ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. ITALY ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 294. ITALY ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 295. ITALY ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 296. SPAIN ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. SPAIN ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 304. SPAIN ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 316. INDIA ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. INDIA ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 323. INDIA ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 324. INDIA ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 325. INDIA ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 326. JAPAN ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 327. JAPAN ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. JAPAN ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 329. JAPAN ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 330. JAPAN ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 331. JAPAN ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 332. JAPAN ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 333. JAPAN ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 334. JAPAN ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 335. JAPAN ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 336. AUSTRALIA ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 337. AUSTRALIA ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. AUSTRALIA ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 339. AUSTRALIA ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 340. AUSTRALIA ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 341. AUSTRALIA ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 342. AUSTRALIA ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 343. AUSTRALIA ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 344. AUSTRALIA ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 345. AUSTRALIA ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 346. SOUTH KOREA ACTIVIN-A MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 347. SOUTH KOREA ACTIVIN-A MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 348. SOUTH KOREA ACTIVIN-A MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 349. SOUTH KOREA ACTIVIN-A MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 350. SOUTH KOREA ACTIVIN-A MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 351. SOUTH KOREA ACTIVIN-A MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 352. SOUTH KOREA ACTIVIN-A MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 353. SOUTH KOREA ACTIVIN-A MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 354. SOUTH KOREA ACTIVIN-A MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 355. SOUTH KOREA ACTIVIN-A MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)